ZURICH, Sept. 1 (Reuters) - The Swiss blue-chip SMI was seen opening nearly 1 percent down at 8737.53 points on Tuesday, according to premarket indications by bank Julius Baer .
The following are some of the main factors expected to affect Swiss stocks:
The Swiss crop chemicals maker said it has won U.S. approval for its fungicide solatenol, adding global peak sales could reach $1 billion.
For more click on
The drugmaker said it received EU approval for Tafinlar and Mekinist, the first combination approved for patients with an aggressive form of melanoma.
For more click
** UBS Group said it has completed its SESTA procedure and will pay a supplementary dividend of 0.25 Swiss francs on Sept. 22. It’s also starting a new marketing campaign with celebrity photographer Anne Leibowitz.
** Alpiq sold its 26 percent share of Gommmerkraftwerke AG to Group E in western Switzerland. The Swiss power producer didn’t release the price of the transaction.
** Leclanche says it won a “major order” for solar street lighting solutions in Saudi Arabia and a new battery order for automatic-guided vehicles.
** Helvetia Holdings AG says its combined ratio in the first half of 2015 was 92.4 percent, compared to 94 percent in the first half of last year.
** Hiag said it had net income in the first half of 24.2 million Swiss francs ($25.17 million) and that its operating income rose 9 percent.
** Romande Energie boosted its gross profit by 4 percent and expects to achieve a full-year business performance in line with the first six months of the year, not including exceptional items.
The Swiss manufacturing PMI is due at 0730 GMT. ($1 = 0.9615 Swiss francs) (Reporting by Zurich newsroom)